Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Promiliad

Promiliad
2002 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Later Stage VC LATEST DEAL TYPE
2 INVESTORS
Description

Provider of a drug discovery platform intended to focus on the development of new antibacterial and antifungal agents. The company's platform uses a technology called ReBACS (Recombinant Biotechnology Assisted Combinatorial Synthesis) which offers a complex and rich structural diversity, enabling scientists to simplify the synthetic challenge in drug discovery and increases the probability of generating new lead compounds.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • Post Box 10
  • Alberton, MT 59820
  • United States

+1 (406) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Promiliad’s full profile, request a free trial.

Promiliad Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC Completed Generating Revenue
5. Grant 01-Jul-2013 00000 Completed Generating Revenue
4. Grant 01-Jul-2011 00.000 Completed Generating Revenue
3. Grant 15-Jul-2009 00000 Completed Generating Revenue
2. Grant 01-May-2007 $1.28M Completed Startup
1. Grant 15-Jul-2005 $237K Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Promiliad Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
TechGROWTH Ohio Venture Capital Minority 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0

Promiliad Executive Team (3)

Name Title Board
Seat
Contact
Info
Stephen Bergmeier Ph.D Co-Founder, Chief Operating Officer & Director, Medicinal Chemistry
Mark McMills Ph.D Co-Founder & CSO
Priestley Nigel Co-Founder and Owner